Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2269-2275

  Zheng, Xi ^a,b   Cui, Xiao Xing ^a   Gao, Zhi ^c   Verano, Michael ^a   Huang, Mou Tuan ^a   Liu, Yue ^a   Rabson, Arnold B ^d   Conney, Allan H ^a,b,e  

^a RUTGERS UNIVERSITY   (United States)

^b GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d CHILD HEALTH INSTITUTE OF NEW JERSEY   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

c Jun NH2 terminal kinase; Chemotherapy; Gemcitabine; Pancreatic cancer; Phorbol ester

Indexed keywords

GEMCITABINE; PHORBOL 13 ACETATE 12 MYRISTATE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; ENZYME ACTIVATION; FEMALE; HUMANS; MAP KINASE KINASE 4; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869764138     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1651     Document Type: Article

References (51)

1. Zavoral M, Minarikova P, Zavada F, Salek C and Minarik M: Molecular biology of pancreatic cancer. World J Gastroenterol 17: 2897-2908, 2011.
2. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
3. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004. (Pubitemid 38410779)
4. Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 99: 6-13, 2008. (Pubitemid 351920234)
5. Zalatnai A: Pancreatic cancer - a continuing challenge in oncology. Pathol Oncol Res 9: 252-263, 2003.
6. Ahrendt SA and Pitt HA: Surgical management of pancreatic cancer. Oncology 16: 725-734, 2002.
7. Wray CJ, Ahmad SA, Matthews JB and Lowy AM: Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterol 128: 1626-1641, 2005. (Pubitemid 40692556)
8. Hilbig A and Oettle H: Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev Anticancer Ther 8: 511-523, 2008. (Pubitemid 351818346)
9. Toschi L, Finocchiaro G, Bartolini S, Gioia V and Cappuzzo F: Role of gemcitabine in cancer therapy. Future Oncol 1: 7-17, 2005.
10. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and von Hoff DD: Improvements in survival and clinical benefit with as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
11. Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF, Liu XJ, Cao GS, Newmark HL, Conney AH and Chang RL: Effect of intravenous infusions of 12-0-tetradecanoyl- phorbol-13-acetate (TPA) in patients with myelocytic leukemia: Preliminary studies on therapeutic efficacy and toxicity Proc Natl Acad Sci USA 95: 5357-5361, 1998. (Pubitemid 28208602)
12. Strair RK, Schaar D, Goodell L, Aisner J, Chin KV, Eid J, Senzon R, Cui XX, Han ZT, Knox B, Rabson AB, Chang R and Conney A: Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 8: 2512-2518, 2002. (Pubitemid 34856333)
13. Schaar D, Goodell L, Aisner J, Cui XX, Han ZT, Chang R, Martin J, Grospe S, Dudek L, Riley J, Manago J, Lin Y, Rubin EH, Conney A and Strair RK: A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol 57: 789-795, 2006.
14. Zheng X, Chang RL, Cui XX, Kelly KA, Shih WJ, Lin Y, Strair R, Suh J, Han ZT, Rabson A and Conney AH: Synergistic effects of clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic acid, 1alpha,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells. Oncol Res 12: 419-427, 2000. (Pubitemid 33781094)
15. Hansson A, Marín YE, Suh J, Rabson AB, Chen S, Huberman E, Chang RL, Conney AH and Zheng X: Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-êB inhibitor. Int J Oncol 27: 941-948, 2005.
16. Avila GE, Zheng X, Cui XX, Ryan AD, Hansson A, Suh J, Rabson AB, Chang RL, Shih WJ, Lin Y, Crowell P, Lu YP, Lou YR and Conney AH: Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice. J Pharmacol Exp Ther 315: 170-187, 2005. (Pubitemid 41380510)
17. Bond JA, Gescher AJ, Verschoyle RD, Lemoine NR, Errington R, Wiltshire M, Smith PJ and Wynford-Thomas D: Cytotoxic action of phorbol esters on human pancreatic cancer cells. Int J Cancer 121: 1445-1454, 2007. (Pubitemid 47328702)
18. Salabat MR, Ding XZ, Flesche JB, Ujiki MB, Robin TP, Talamonti MS, Bell RH Jr and Adrian TE: On the mechanisms of 12-O-tetradecanoylphorbol-13-acetate- induced growth arrest in pancreatic cancer cells. Pancreas 33: 148-155, 2006. (Pubitemid 44174562)
19. Detjen KM, Brembeck FH, Welzel M, Kaiser A, Haller H, Wiedenmann B and Rosewicz S: Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J Cell Sci 113: 3025-3035, 2000.
20. Ploszaj T, Motyl T, Orzechowski A, Zimowska W, Wareski P, Skierski J and Zwierzchowski L: Antiapoptotic action of prolactin is associated with up-regulation of Bcl-2 and downregulation of Bax in HC11 mouse mammary epithelial cells. Apoptosis 3: 295-304, 1998. (Pubitemid 128691553)
21. Zheng X, Chang RL, Cui XX, Avila GE, Lee S, Lu YP, Lou YR, Shih WJ, Lin Y, Reuhl K, Newmark H, Rabson A and Conney AH: Inhibitory effect of12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res 64: 1811-1820, 2004. (Pubitemid 38428706)
22. Zheng X, Cui XX, Huang MT, Liu Y, Shih WJ, Lin Y, Lu YP, Wagner GC and Conney AH: Inhibitory effect of voluntary running wheel exercise on the growth of human pancreatic Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice. Oncol Rep 19: 1583-1588, 2008.
23. Zhao L, Wientjes MG and Au JL: Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994-8004, 2004. (Pubitemid 39587541)
24. Hsu JC: Comparisons: Theory and Methods. Chapman and Hall, New York, NY, 1996.
25. Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN and Conney AH: Effects of 12-O- tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice. Clin Cancer Res 12: 3444-3451, 2006.
26. Van Duuren BL: Tumor-promoting agents in two-stage carcinogenesis. Prog Exp Tumor Res 11: 31-68, 1969.
27. Hecker E: Structure-activity relationships in diterpene esters irritant and cocarcinogenic to mouse skin. In: Mechanisms of Tumor Promotion and Cocarcinogenesis. Slaga TJ, Sivak AJ and Boutwell RK (eds). Raven, New York, NY, pp11-49, 1978.
28. Huberman E and Callaham MF: Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci USA 76: 1293-1297, 1979. (Pubitemid 9143726)
29. Lotem J and Sachs L: Regulation of normal differentiation in mouse and human myeloid leukemic cells by phorbol esters and the mechanism of tumor promotion. Proc Natl Acad Sci USA 76: 5158-5162, 1979. (Pubitemid 10231836)
30. Rovera G, O'Brien TG and Diamond L: Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 204: 868-870, 1979. (Pubitemid 9207698)
31. Cui XX, Chang RL, Zheng X, Woodward D, Strair R and Conney AH: A sensitive bioassay for measuring blood levels of 12-O-tetradecanoylphorbol-13- acetate (TPA) in patients: preliminary pharmacokinetic studies. Oncol Res 13: 169-174, 2002. (Pubitemid 38173037)
32. Voutsadakis IA: Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 3: 153-164, 2011.
33. Greenhalf W and Thomas A: Combination therapy for the treatment of pancreatic cancer. Anticancer Agents Med Chem 11: 418-426, 2011.
34. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB III: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 20: 3270-3275, 2002. (Pubitemid 34831525)
35. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and Miller LL: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776-3783, 2004. (Pubitemid 41095218)
36. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C and de Gramont A; GERCOR; GISCAD: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516, 2005.
37. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, von Hoff D, Arning M and Kindler HL: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16: 1639-1645, 2005. (Pubitemid 41510138)
38. Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, de Jager RL, Eckhardt SG and O'Reilly EM: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24: 4441-4447, 2006. (Pubitemid 46630982)
39. Kim YR, Byun HS, Jeon J, Choi BL, Park KA, Won M, Zhang T, Shin S, Lee H, Oh J and Hur GM: Apoptosis signal-regulating kinase1 is inducible by protein kinase C ä and contributes to phorbol ester-mediated G1 phase arrest through persistent JNK activation. Cell Biochem Biophys 61: 199-207, 2011.
40. Engedal N, Korkmaz CG and Saatcioglu F: C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 21: 1017-1027, 2002. (Pubitemid 34174514)
41. Ikezoe T, Yang Y, Taguchi H and Koeffler HP: JNK interacting protein 1 (JIP-1) protects LNCaP prostate cancer cells from growth arrest and apoptosis mediated by 12-0-tetradecanoylphorbol-13-acetate (TPA). Br J Cancer 90: 2017-2024, 2004. (Pubitemid 38746347)
42. Tahara E, Kadara H, Lacroix L, Lotan D and Lotan R: Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol Ther 8: 801-807, 2009.
43. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
44. Ruiz van Haperen VW, Veerman G, Vermorken JB and Peters GJ: 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46: 762-766, 1993. (Pubitemid 23262974)
45. Tolis C, Peters GJ, Ferreira CG, Pinedo HM and Giaccone G: Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35: 796-807, 1999. (Pubitemid 29258151)
46. Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, van Bockstaele DR, Vermeulen K, Lenjou M, de Pooter CM, Vermorken JB and Lardon F: Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 57: 1075-1083, 2003. (Pubitemid 37324126)
47. Bouffard DY and Momparler RL: Comparison of the induction of apoptosis in human leukemic cell lines by difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 19: 849-856, 1995. (Pubitemid 26009454)
48. Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM and Giaccone G: Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 6: 203-212, 2000. (Pubitemid 30064995)
49. Teraishi F, Zhang L, Guo W, Dong F, Davis JJ, Lin A and Fang B: Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett 579: 6681-6687, 2005. (Pubitemid 41682458)
50. Osada S, Tomita H, Tanaka Y, Tokuyama Y, Tanaka H, Sakashita F and Takahashi T: The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res 28: 45-50, 2008. (Pubitemid 351362879)
51. Kreutzer JN, Ruzzene M and Guerra B: Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. BMC Cancer 10: 440, 2010.